Want to see VTAK full AI Analyst Report?
Top Page
Catheter Precision
(NYSE MKT:VTAK)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.84
▼(-53.81% Downside)
Action:Reiterated
Date:06/25/26
The score is held down primarily by weak financial performance—very small revenue scale, severe losses, and sustained cash burn implying ongoing financing needs. Technicals provide some near-term support with improving momentum, but valuation is constrained by negative earnings and no dividend support. Corporate events modestly help liquidity and optionality, though they introduce dilution and execution risk.
Positive Factors
Proprietary product / market position
The company’s core proprietary electrophysiology mapping catheter targets a structural need in cardiac ablation procedures. Proprietary device design and procedure-based consumable sales create recurring, per-procedure revenue potential and a durable foothold in electrophysiology labs if clinical adoption continues.
Negative Factors
Sustained negative operating cash flow
Persistent, large operating cash outflows indicate the company is not yet cash-generative and remains dependent on external funding. Over 2–6 months this raises runway and dilution risk, constrains marketing and scale investments, and limits flexibility to respond to competitive or regulatory needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary product / market position
The company’s core proprietary electrophysiology mapping catheter targets a structural need in cardiac ablation procedures. Proprietary device design and procedure-based consumable sales create recurring, per-procedure revenue potential and a durable foothold in electrophysiology labs if clinical adoption continues.
Read all positive factors
Catheter Precision (VTAK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.29M
Dividend YieldN/A
Average Volume (3M)309.34K
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue Growth130.35%
EPS Growth92.24%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-6.79
Shares Outstanding2,692,473
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap5.50
Enterprise Value/Revenue11.34
Enterprise Value/Gross Profit12.39
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Catheter Precision Business Overview & Revenue Model
Company Description
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by ...
How the Company Makes Money
Catheter Precision makes money primarily by selling its electrophysiology mapping catheters and related disposables used in hospital catheterization/electrophysiology labs during arrhythmia procedures. Revenue is generated on a per-procedure basis...
Catheter Precision Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
35
Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 819.00K | 420.00K | 442.00K | 14.00K | 22.00K |
| Gross Profit | 756.00K | 378.00K | 412.00K | -147.00K | -1.54M |
| EBITDA | -17.11M | -11.30M | -15.11M | -22.37M | -25.85M |
| Net Income | -17.18M | -16.64M | -70.57M | -26.86M | -25.07M |
Balance Sheet | |||||
| Total Assets | 15.86M | 27.77M | 30.74M | 16.84M | 21.04M |
| Cash, Cash Equivalents and Short-Term Investments | 88.00K | 2.87M | 3.56M | 15.86M | 15.04M |
| Total Debt | 3.85M | 1.79M | 372.00K | 0.00 | 2.26M |
| Total Liabilities | 9.21M | 16.01M | 9.54M | 7.58M | 7.37M |
| Stockholders Equity | 7.05M | 11.76M | 21.19M | 9.26M | 13.67M |
Cash Flow | |||||
| Free Cash Flow | -8.31M | -9.34M | -20.70M | -22.59M | -27.89M |
| Operating Cash Flow | -8.30M | -9.27M | -20.62M | -22.57M | -27.63M |
| Investing Cash Flow | 167.00K | -67.00K | -61.00K | 21.00K | 3.80M |
| Financing Cash Flow | 5.34M | 8.65M | 8.39M | 23.36M | 14.96M |
Catheter Precision Technical Analysis
Negative
1.81
Price Trends
0.93
Negative
1.15
Negative
1.71
Negative
Market Momentum
0.04
Negative
56.42
Neutral
36.05
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTAK, the sentiment is Negative. The current price of 1.81 is above the 20-day moving average (MA) of 1.01, above the 50-day MA of 0.93, and above the 200-day MA of 1.71, indicating a bearish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 56.42 is Neutral, neither overbought nor oversold. The STOCH value of 36.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTAK.
Catheter Precision Risk Analysis
Catheter Precision disclosed 40 risk factors in its most recent earnings report. Catheter Precision reported the most risks in the "Production" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Issued shares of our convertible preferred stock are convertible into a substantial number of shares of common stock that, upon conversion, will significantly dilute our existing common stockholders. Q1, 2026
2.
We may issue additional series of convertible preferred stock under the Series C Purchase Agreements that, upon issuance and conversion, could result in extraordinary additional dilution to our existing common stockholders. Q1, 2026
3.
A delay or failure to identify, invest in and implement important technology, business and other initiatives could have a material adverse effect on FLYTE's business. Q1, 2026
Catheter Precision Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $2.29M | -0.12 | -173.74% | ― | 130.35% | 92.24% | |
46 Neutral | $42.52M | -0.14 | -49.65% | ― | -95.74% | -118.94% | |
43 Neutral | $1.95M | -0.05 | -191.39% | ― | ― | 81.30% | |
43 Neutral | $1.11M | >-0.01 | -6046.59% | ― | -0.20% | 91.63% | |
40 Underperform | $8.26M | -0.63 | -220.42% | ― | ― | 51.71% |
* Healthcare Sector Average
VTAK
Catheter Precision
0.85
-3.56
-80.75%
NUWE
Nuwellis
3.05
-336.96
-99.10%
AEMD
Aethlon Medical
0.82
-10.98
-93.03%
PAVM
PAVmed
5.94
-12.54
-67.86%
HSCS
Heart Test Laboratories, Inc.
2.51
-1.39
-35.64%
Catheter Precision Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Catheter Precision Makes Strategic Investment in Volato Group
Positive
Jun 8, 2026
On June 7, 2026, Catheter Precision, Inc. agreed to participate in a private placement by purchasing 2,941,176 shares of Volato Group, Inc. common stock at $0.34 per share, for a total of $1 million, a stake whose market value was approximately eq...
M&A TransactionsPrivate Placements and Financing
Catheter Precision Raises Capital Through New Preferred Stock
Positive
Apr 23, 2026
On April 21, 2026, Catheter Precision closed the sale of 3,470 shares of its newly created Series C-2 Convertible Preferred Stock at $1,000 per share, raising gross proceeds of $3.47 million to be used for working capital and general corporate nee...
Business Operations and StrategyShareholder MeetingsStock Split
Catheter Precision Shareholders Approve Reverse Split, Capital Changes
Neutral
Apr 15, 2026
On April 15, 2026, Catheter Precision held a Special Meeting of stockholders where approximately 49.5% of outstanding common shares were represented. Shareholders approved the issuance of common shares underlying the company’s Series C-1, C-...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.